Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
CardioNerds @AHA23: ORBITA-2: PCI for Stable Angina
Author(s): Rasha Al-Lamee , Christopher Rajkumar , Nazli Okumus Added: 1 year ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA… View more

Intervention
Author(s): Rasha Al-Lamee , Michael Foley Added: 1 year ago
ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537).This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and… View more

Prevention & Chronic Conditions
Yield and Characterisation of CFT in ANOCA
Author(s): Johanna McChord , Astrid Hubert , Udo Sechtem , et al Added: 8 months ago

Prevention & Chronic Conditions
Evolution of Coronary Artery Spasm
Author(s): John F Beltrame , Peter Ong , Filippo Crea Added: 1 year ago

Prevention & Chronic Conditions
Author(s): Juan Carlos Kaski , Hiroaki Shimokawa Added: 1 year ago

Vascular Disease and Surgery

Prevention & Chronic Conditions
Separated Vasoreactivity Testing of ACH
Author(s): Shozo Sueda , Tomoki Sakaue Added: 9 months ago

Prevention & Chronic Conditions
Perfect Vasoreactivity Test
Author(s): Shozo Sueda , Tomoki Sakaue Added: 10 months ago

Prevention & Chronic Conditions

Intervention
Coronary Spasm: Ethnic and Sex Differences
Author(s): Peter Ong , Astrid Hubert , Maike Schwidder , et al Added: 2 years ago

Demographic

CV Disease in Special Populations
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 1 month ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
ECG Exercise Stress Test in Coronary Artery Disease
Author(s): Gaetano Antonio Lanza Added: 1 month ago

Guidelines & Statements